Antitrust Enforcement In Health Care: A Risky And Evolving Landscape
In the last 18 months, seven companies and four executives in the generic pharmaceuticals manufacturing sector were charged with antitrust violations, amassing penalties of over $426m. And this month, the Department of Justice Antitrust Division brought its first ever criminal charges for a conspiracy to lower wages to workers against the former owner of a physical therapist staffing company. With enforcement efforts ramping up – and COVID-19 adding additional scrutiny – health care companies will need a comprehensive antitrust compliance program to avoid enforcement actions.
You may also be interested in...
Pink Sheet reporters and editors discuss whether a new report on generic drug prices will affect efforts to green-light government price negotiations, Eli Lilly’s untitled letter for promotion on Instagram, and Oncopeptides deciding to withdraw its accelerated approval withdrawal.
Akili Interactive Labs, which developed the first prescription-only video-game-based platform to be cleared for marketing by the US FDA, recently announced plans to go public through a SPAC merger with Social Capital Suvretta Holdings Corp. I. See what Chamath Palihapitiya, CEO of Social Capital and CEO of Social Capital Holdings Corp. I, said about it here.
Several new drugs are now on track for an EU marketing authorization after getting the EMA’s thumbs up this week.